Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2015 by GITR, Inc.
Sponsor:
Collaborator:
Cancer Research Institute, New York City
Information provided by (Responsible Party):
GITR, Inc.
ClinicalTrials.gov Identifier:
NCT01239134
First received: November 9, 2010
Last updated: November 18, 2015
Last verified: November 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2016
  Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)